Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Aims: Reducing elevated low-density lipoprotein cholesterol (LDL-C) is central to global efforts to prevent myocardial infarction (MI). While many studies have evaluated LDL-C-lowering therapies in first-time and recurrent MI prevention, direct comparisons of their relative efficacy are lacking. Therefore, we conducted a systematic review and meta-analysis to compare the efficacy of LDL-C-lowering therapies in first-time versus recurrent MI prevention.
Methods: We searched three databases until November 30, 2024, for randomized controlled trials (RCTs) with at least 1,000 patient-years of follow-up. Efficacy was quantified as relative risk (RR) with 95% confidence intervals (CIs). Differences in benefit magnitude were assessed using Cochran's Q test. Data were pooled with a random-effects model, and heterogeneity was measured using the I2 statistic. Additionally, we applied the Cochrane Risk of Bias Tool to evaluate study quality and utilized the GRADE method to assess the certainty of the evidence.
Results: This study included 22 large-scale RCTs involving 180,304 participants. In first-time MI prevention, LDL-C-lowering therapies achieved a remarkable 38% reduction in MI risk (12 RCTs; 79,604 participants; RR, 0.62 [95% CI, 0.55-0.69]; P <0.001). In recurrent MI prevention, these therapies were associated with a more modest but significant 16% risk reduction (11 RCTs; 100,700 participants; RR, 0.84 [95% CI, 0.80-0.88]; P <0.001). Importantly, the benefit magnitude between the two groups was significantly different (Q=22.63; P <0.001), highlighting the greater relative benefit in first-time MI prevention. Furthermore, the robustness of our findings was consistently supported by leave-one-out analyses, the absence of publication bias, high-quality GRADE evidence, and subgroup and sensitivity analyses.
Conclusion: Our findings suggest that LDL-C-lowering therapies may offer a greater benefit in preventing first-time MI compared to recurrent MI.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1093/eurjpc/zwaf336 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Lipoprotein(a) at a "Tipping Point": case to move to universal screening.
Am J Prev Cardiol
September 2025
Division of Cardiovascular Medicine, University of California San Diego, La Jolla, CA, USA.
Elevated lipoprotein(a) [Lp(a)] is well established as a common risk factor for atherosclerotic cardiovascular disease (ASCVD). Lp(a) levels are >90 % genetically determined. However, Lp(a) remains very underrecognized as a cardiovascular risk factor with low rates of testing.
View Article and Find Full Text PDFEffect of evolocumab on saphenous vein graft patency after coronary artery bypass surgery (NEWTON-CABG CardioLink-5): an international, randomised, double-blind, placebo-controlled trial.
Lancet
August 2025
Department of Anesthesia, St Michael's Hospital-Unity Health Toronto, Toronto, ON, Canada; Department of Pharmacology and Toxicology, University of Toronto, Toronto, ON, Canada; Department of Anesthesiology and Pain Medicine, University of Toronto, Toronto, ON, Canada; Department of Physiology, Univ
Background: Saphenous vein graft (SVG) failure remains a substantial challenge after coronary artery bypass graft (CABG). LDL cholesterol (LDL-C) is a causal risk factor for atherosclerosis, but its role in SVG failure is not well established. We evaluated whether early initiation of intensive LDL-C lowering with evolocumab could reduce SVG failure.
View Article and Find Full Text PDFDemystifying the nuances of the lipid patient: a guide for primary care providers.
Am J Prev Cardiol
September 2025
Abington Family Medicine, Jefferson Health, Jenkintown, PA, USA.
Atherosclerosis, a major cause of mortality and morbidity in the United States (US), is driven by complex factors, including the cumulative burden of low-density lipoprotein cholesterol (LDL-C) and other atherogenic lipids and lipoproteins. Lipid management in US primary care aims to prevent atherosclerotic cardiovascular disease (ASCVD) events through screening and LDL-C lowering to risk-based goals. However, lipid screening and ASCVD treatment is often inadequate, with few patients meeting LDL-C goals in clinical practice.
View Article and Find Full Text PDFImpact of a Meds-to-Beds PCSK9i Initiation Program on LDL-C in Patients Undergoing ASCVD Revascularization.
JACC Adv
August 2025
Division of Cardiology, Montefiore Health System/Albert Einstein College of Medicine, Bronx, New York, USA. Electronic address:
Background: Despite proven benefits of low-density lipoprotein cholesterol (LDL-C) lowering in secondary prevention of atherosclerotic cardiovascular disease, goal achievement remains suboptimal.
Objectives: The authors tested whether early use of guideline-recommended proprotein convertase subtilisin/kexin type 9 inhibitor (PCSK9i) monoclonal antibodies (mAbs) through a meds-to-beds (M2B) program improved LDL-C goal attainment postrevascularization.
Methods: Using a dedicated M2B program, we prospectively included patients undergoing coronary or peripheral artery revascularization, on maximally tolerated statin therapy, and with LDL-C ≥70 mg/dL.
Estimate of Brazilians Under Secondary Prevention of Cardiovascular Events Who Do Not Achieve LDL Cholesterol Targets with Lipid-Lowering Therapy.
Arq Bras Cardiol
August 2025
Novartis Biociências AS, São Paulo, SP - Brasil.
Background: The 2017 Brazilian Guideline on Dyslipidemias recommends a low-density lipoprotein (LDL-c) target of <50 mg/dL for patients under secondary prevention of cardiovascular events, with statin therapy and the addition of ezetimibe if necessary. For patients who do not achieve this target, additional pharmacotherapy is indicated.
Objectives: This study combined population data from the Brazilian Unified Health System (SUS) and the supplementary health system, epidemiological data, and the Delphi method, with participation from 29 specialists in the first round and 24 in the second, to estimate the size of the secondary prevention population not achieving LDL-c targets.